What changed in policy—or in our evidence—and how the pathway changed

Added selected 2026 test-manufacturing, imported shelf-life, PSUR and DPCO amendments; clarified conditional clinical waivers and separate scheme, supply and later-claim checks.

Use 13 reference checks across parallel research contexts. Actual product, patient, provider, price, contract and stock decisions remain case-specific.

Added current CSP rules and dated 2026 HTA/PNDF adoption evidence; clarified GAMOT continuity, inpatient shadow billing and procurement transition. First treatment is separate from later claim settlement.

Use the nine checks as references for the chosen financing context; verify product, patient, provider, contract and stock conditions separately.

Updated the existing pathway using PMK 5/2026, the Fornas decision applying from April 2026 and the 2026 addendum instructions. Clarified HTA routing, competent SAS authorities, catalogue and claim-value conditions. This is an Atlas research revision; official instruments retain their own dates.

Eight reference checks distinguish the financing scenario from eligibility, procurement from reimbursement, and actual first use from later settlement. No individual product, facility or patient is approved by these selections.

Updated the pathway for Circular 32/2026, effective 1 October 2026, and its earlier-filing transitions. Clarified prescription wholesale-price publication, BHYT list and facility conditions, purchasing scope and 2026 facility claims rules. This is an Atlas research revision; the separate instruments retain their own official dates.

Explore Vietnam through nine checks, with first treatment shown before later claims settlement. Compare BHYT and non-BHYT contexts while keeping product, patient and facility eligibility separate.

Clarified ACTD/ICH CTD and conditional assessment routes, the 2026 NLEM categories and entry-specific commencement, conditional HTA and negotiation, and scheme-specific funding and supply. Replaced outdated links and distinguished the 2021 HTA methods and historical mechanism references from current product requirements. This is an Atlas research revision, not one new policy commencement date.

Plan registration, NLEM selection, public-scheme payment, procurement and patient authorisation separately. Confirm the exact entry, funding context and supply conditions; the research choices do not establish product eligibility or funding.

Reviewed the recognition pilot, D1 entry and budget-impact requirements, national and facility formularies, special approval, MASc and business licensing. Clarified waiting-period exceptions, scheme-specific duration and price-declaration boundaries. Sector selections describe a research context; official dates remain separate from this Atlas revision.

Plan product registration separately from MOH listing, institution adoption, procurement and supply. Confirm the relevant sector, route conditions, declared price period and permits or licences; a research selection does not establish eligibility or funding.

Reviewed the existing MFDS–HIRA–NHIS–MOHW pathway, the31October reassessment evidence deadline, phased2026pricing rules and eCTDv4.0 transition. Corrected flexible-price contracts from a broadly pending label to the published provider implementation layer, and made evidence and RSA research views independent. Official dates remain separate from this Atlas record.

Keep regulatory approval, HIRA evidence review, NHIS agreements, effective MOHW listing and provider claims separate. Check the applicable filing date, contractual eligibility and actual price notice before relying on a route or price.

Reviewed the existing TGA–PBAC–PBS pathway, current disclosure/stockholding and fee conditions, closed discretion windows and the labelling transition. Replaced the superseded NSW policy reference and clarified current inpatient/outpatient governance. Official policy dates remain separate from this Atlas revision.

Plan regulatory acceptance, PBAC value assessment, pricing and agreements, effective PBS listing, and institution-specific supply separately; use the correct filing window and product-specific price and label rules.

Updated the current pathway for the announced ACE–HSA Priority Track, 2027/2028 DAC calendars, route-specific evidence and pricing requirements, and the distinction between subsidy listings, insurance claims and institutional supply. Official policy and implementation dates remain separate from this Atlas research revision.

Plan regulatory and funding work separately, check invitation and filing windows, and confirm the applicable list, agreement and hospital supply before estimating patient access.

Reconciled the current national pathway with the 2026 conditional-approval rules, NHI submission and supply deadlines, pricing and maintenance conditions, post-listing CEA procedures and patient-payment phases. This is an Atlas research revision; the official rules have their own effective dates.

Separate regulatory approval, NHI price listing, hospital availability and patient affordability; check the applicable 2026 route, deadlines and adjustment conditions before planning launch.

The 20 October notice confirms that onsite negotiation, bidding and commercial-insurance price discussions took place in September and that results were confirmed onsite. Relevant companies can now download and sign agreements through the national platform. Signing is distinct from final directory publication, its stated commencement date, provincial settlement and actual stock. Neither this notice nor a planned publication month establishes those later events.

Signing is distinct from final directory publication, its stated commencement date, provincial settlement and actual stock. Neither this notice nor a planned publication month establishes those later events.

The 17 April guidance clarifies reimbursement for label-consistent maintenance treatment by reference to dosage/administration, not only the indications section, subject to applicable directory and payment restrictions. For an approved combination, the latest approved label can establish the older components’ indication basis for reimbursement purposes; non-directory medicines and medicines with explicit payment restrictions remain excluded from this combination clarification. Other additions, removals or substitutions in a regimen do not receive blanket approval. The guidance retains existing local handling pending case-specific clarification; it defines payment boundaries, not clinical prescribing advice or guaranteed individual reimbursement.

Other additions, removals or substitutions in a regimen do not receive blanket approval. The guidance retains existing local handling pending case-specific clarification; it defines payment boundaries, not clinical prescribing advice or guaranteed individual reimbursement.

Boundary: an approved indication can establish eligibility for a directory-adjustment application. Changes to dosage or safety wording do not automatically qualify as a significant indication change under the 2026 application category. The actual 2026 GCP has six chapters and 54 articles. Participant protection, proportionate quality management, auditable responsibilities and data governance are supported by articles 4, 6, 9, 18–20, 29, 31–44 and 48–53. These general trial duties do not establish a medicine-specific approval or review timeline.

The actual 2026 GCP has six chapters and 54 articles. Participant protection, proportionate quality management, auditable responsibilities and data governance are supported by articles 4, 6, 9, 18–20, 29, 31–44 and 48–53. These general trial duties do not establish a medicine-specific approval or review timeline.

The medicine-guidance notice of 14 January 2026 was a consultation, with comments due 30 January at 17:00. That historical status must not be generalised into a claim that no later rule exists. The March national pricing policy calls for evidence to inform directory and payment-standard adjustment. Apply the current instrument and actual product/task scope. Do not infer a fixed drug repricing formula, automatic loss of reimbursement or a drug requirement from a medical-service pricing pilot.

Apply the current instrument and actual product/task scope. Do not infer a fixed drug repricing formula, automatic loss of reimbursement or a drug requirement from a medical-service pricing pilot.

Clinical-trial permission and GCP compliance do not themselves authorise marketing. Marketing approval issues a drug registration certificate with approved manufacturing, quality, label and product-information annexes. Under the regulations effective15May2026, certificates last five years: domestic holders seek re-registration from the provincial authority, overseas holders from the national authority. Fact: 2026 GCP prioritises participants' rights, safety and wellbeing. Quality by design, critical-to-quality factors and risk-proportionate quality management support reliable results and traceable data. Responsibilities of sponsors, investigators/institutions, ethics review, laboratories and contracted services must remain auditable throughout the trial. Effective-date boundary: the revised requirements apply from 1 September 2026, when Announcement No. 57 of 2020 is repealed. Record the announcement date of 21 May 2026, website publication on 8 June, commencement on 1 September and Atlas content update on 4 September separately. Fact: the statutory label defines approved indications, dosage/administration and safety information. Reimbursement must also meet the directory's restricted payment scope. Boundary: an approved indication can establish eligibility for a directory-adjustment application. Changes to dosage or safety wording do not automatically qualify as a significant indication change under the 2026 application category.

NMPA authorisation is separate from reimbursement access

The 9 May interpretation concerns consultation drafts. Its publication-day eligibility wording and inclusive price-warning explanation must not override the final 31 May notice and attachments. Current pathway citations now use the final materials; the old interpretation remains explicitly labelled as draft history.

Use final rules alongside clearly labelled draft history

Since 2025, renewal ratios A and B use medicine expenses within the reimbursement scope, including the relevant insured-person costs at designated institutions and pharmacies. They do not use fund payments alone or all company sales. Actual expense data come from NHSA; budget data for 2024-onward new negotiations/renegotiations come from the signed result confirmation, while simplified-renewal budgets use that year’s platform declaration. For the 2026 expiring-agreement calculation, actual expenses combine full-year 2025 with January–April 2026 annualised by multiplying by three; the annual average is half that sum. Ratio A compares actual covered-scope expenses with the budget. Ratio B compares the added budget for an expanded scope with the higher of the original-scope budget and actual expenses. Non-expiring agreements have a separate one-year scope-expansion basis. Simplified renewal requires all eligibility conditions, including exclusivity, actual expenses no more than 200% of budget, reasonable future growth within the specified 100% limits, no major market change and no regular-directory transfer condition. For unchanged scope and fewer than four years, A bands up to 110%, 140%, 170% and 200% carry base reductions of 0, 5, 10 and 15 percentage points. Where A exceeds 110%, annual-expense bands may add 0, 2, 4, 6 or 10 points; a base band alone is not a final price prediction. Scope expansion applies the original-scope adjustment and then the additional-scope adjustment. The FAQ explains that the four-year concession halves the final combined reduction, rather than independently halving each component before compounding. Prior-year A reductions, expiry and product-category exceptions require separate checks; this overview does not calculate an individual renewal price.

Use the correct expense basis for renewal

Regular class B transfer covers non-exclusive medicines or negotiated medicines whose agreement expires in the adjustment year and whose continuous negotiated-list history reaches eight years. Eight calendar years alone do not cancel an unexpired agreement; the FAQ preserves complete two-year agreements signed earlier for new indications. For a qualifying eight-year exclusive medicine, compare the simplified-renewal reduction with a 10-point reduction when annual average covered-scope actual expenses exceed CNY300 million, and use the higher. A major market change instead leads to renegotiation before transfer. Government-priced medicines, volume-based procurement and non-exclusive medicines follow their distinct standard-setting rules. Eligible class 1 chemical, therapeutic-biological and traditional Chinese medicines may request renegotiation rather than the simplified route under the stated A conditions; the result is not guaranteed to be the formula price. Failure in that renewal branch can remove the medicine. Failure to agree a scope expansion has a different fallback: reconsider renewal/renegotiation for the original scope.

Check maturity and renegotiation branches

This non-exclusive directory-entry process excludes national volume-based procurement winners and government-priced medicines. At least one eligible offer must be no higher than the assessed payer willingness to pay. The lowest submitted offer sets the generic-name standard, subject to a floor of 70% of that willingness-to-pay amount; the floor does not raise the company’s own promised supply price. After successful bidding, participating firms commit to supply designated institutions and pharmacies nationwide at no more than their own bids. The formal rule flags generic-name platform prices strictly above 1.8 times the standard yellow and strictly above three times red, including non-participating firms. These are price warnings, not a new uniform supply price or an automatic exclusion. The bidding result lasts two years. After expiry, expert agreement ordinarily permits regular class B management; national VBP or government pricing can change the applicable standard separately. Prices below the standard are paid on the actual-price basis, while the amount above the standard is borne by the insured person, alongside the applicable local benefit rules.

Separate bidding standards from supply prices

The 2026 initial filing window was 1 June at 09:00 to 10 June at 20:00. Provisional filing required technical review completed by 10 June and approval documents by 3 July; a medicine not pre-filed could not be added later. These are historical 2026 dates, not an open invitation or the 2027 cutoff. The guide’s initial application is online and free, using one continuing organisational account. It does not exempt later negotiation/price-discussion stages from their own material and paper-delivery instructions. Required summary slides must match the application and provide two versions, with economic/price information removed only from the second. The summary-slide limit is ten slides excluding the cover and contents, with a 50M file limit. Evidence should show comparative strengths and weaknesses; the FAQ prefers RCT results and authoritative guidelines. A blank comparator does not itself demonstrate high innovation or a high score, and final comparator feedback at expert review takes precedence over preliminary discussion.

Keep filing stages and evidence materials distinct

A medicine recommended for both basic and commercial-insurance pathways first enters basic-directory negotiation; only failure there proceeds to commercial price discussion. Commercial-directory inclusion is a reference for commercial insurance and mutual aid, not basic-insurance reimbursement or proof that a particular policy pays. A planned October–November publication stage is not an issued final directory. New indications and unlisted specifications need the prescribed adjustment process. The FAQ requires a written request for a missing specification under an already listed generic name, calculation from the negotiated main specification under differential-pricing rules, and agreement on the national standard. A new marketing authorisation or hospital stock record does not substitute for that process. Supply obligations include platform-listing applications, promoting stocking at designated institutions and pharmacies, and reporting implementation data. Unjustified deliberate non-supply can lead to removal and a temporary restriction on new directory applications. Monthly company-specific expense/fund feedback supports renewal data reconciliation; it is not independent proof of availability for every patient.

Follow scope and supply through implementation

The 31 July notice states that a proposed negotiation, bidding or commercial-insurance price discussion grants participation eligibility, not final inclusion in either directory. Check the final directory and payment scope separately. The notice's confirmation and materials deadlines were 1 August at12:00 and10 August at17:00. These belong to that review round; later submissions or results must follow their own official notices. The 6 August twelfth-round VBP notice publishes selected results for implementation within2026, with each locality's notice determining the execution date. Do not treat6August as a single nationwide start date; match the selected pack, supplier and region to the formal lists. The31May formal notice used approval or completed technical review before10June for2026eligibility and announced that, from2027, the cutoff will be the work-plan publication date. Do not reuse the2026date as a2027filing rule.

Use the applicable statutory branch and date; confirm product-specific eligibility separately.

Both recognised-authority initial full marketing authorisations must fall within four years before submission. Reliance-only approvals, including TGA COR, MHRA IRP and HSA abridged/verification, do not qualify as full evaluation. Joint work-sharing can qualify only with the required complete assessment-report sets. An initially provisional approval cannot be used merely because it later became full. The pathway also excludes cases requiring independent New Zealand benefit-risk assessment, including specified blood-derived, exclusively paediatric/pregnancy, gene-therapy and personalised products. The list is not exhaustive; seek advice for the precise product and risk-management requirements. Section 24(5) change applications referred to the Minister are not eligible for verification. Validation starts on payment of the validation fee and allows ten working days excluding missing-information stops. Evaluation Day0 is application-fee receipt; the Day20 RFI,30-day response and Day30 decision framework uses working days in New Zealand time, with the response clock stop. Acceptance and fees do not guarantee consent or Pharmac funding. Full marketing authorisation must not be pending deferral, or have been rejected or withdrawn, by any recognised authority for quality, safety or efficacy reasons. The medicine must not have faced regulatory action that may lead or has led to suspension or revocation of authorisation; two selected approvals do not override these tests.

Check full-approval eligibility and fee-based verification clocks

Anyone may submit an ordinary Schedule funding application, including suppliers, clinicians and the public. Supplier proposals require rights to supply the product and the ability to contract with Pharmac; company applications generally include clinical evidence and a price proposal. Pharmac assesses the evidence and obtains independent clinical advice from PTAC or specialist advisory committees as needed, alongside research and economic analysis. A clinical recommendation helps the assessment but does not determine the final funding decision. Different indications for one molecule can have different application statuses, priority-list positions and access criteria. A single molecule-level funded/not-funded label is insufficient. Published provisional PTAC recommendations can precede the final committee-agreed record. Neither a provisional nor a final clinical recommendation is Pharmac’s confidential cross-portfolio ranking or a commitment to fund.

Funding applications: one medicine may have separate applications for different indications

Purpose: combine several items from one supplier to improve budget and health outcomes. Mechanism: commercial terms may span products, and applications need not advance one by one in priority-list order. A product's public page may not disclose all cross-product terms. Commercially sensitive information must be identified with an explicit confidentiality request; withholding remains subject to the Official Information Act and other applicable law.

Portfolio agreements

Both recognised-authority initial full marketing authorisations must fall within four years before submission. Reliance-only approvals, including TGA COR, MHRA IRP and HSA abridged/verification, do not qualify as full evaluation. Joint work-sharing can qualify only with the required complete assessment-report sets. An initially provisional approval cannot be used merely because it later became full. The pathway also excludes cases requiring independent New Zealand benefit-risk assessment, including specified blood-derived, exclusively paediatric/pregnancy, gene-therapy and personalised products. The list is not exhaustive; seek advice for the precise product and risk-management requirements. Section 24(5) change applications referred to the Minister are not eligible for verification. Validation starts on payment of the validation fee and allows ten working days excluding missing-information stops. Evaluation Day0 is application-fee receipt; the Day20 RFI,30-day response and Day30 decision framework uses working days in New Zealand time, with the response clock stop. Acceptance and fees do not guarantee consent or Pharmac funding.

Check full-approval eligibility and fee-based verification clocks

Pharmac generally needs acceptable commercial terms before it can support a funding decision. A listing agreement may specify the agreed price, rebates, access criteria and protection against delisting or subsidy reductions. It may also cover several products from the same supplier. A rebate can reduce the net unit price for all funded units or apply only to expenditure above a threshold. Discounts, two-part pricing and other expenditure-management mechanisms are also possible. The Schedule shows public subsidies and prices, which do not reveal net costs after confidential rebates. Confidentiality is subject to applicable disclosure law and the actual agreement: the published standard template expressly recognises Official Information Act and other legal disclosure obligations. A portfolio agreement may change the apparent acceptable price of an individual product. Comparison pages should identify this as a system-level commercial feature rather than imply a universal net-price formula. The published listing agreement is a template. Product, price, listing date and minimum stock belong in Annex1; negotiated special terms belong in Annex2 and prevail over inconsistent standard terms. It does not prove any particular supplier’s executed price, rebate, term or stock commitment. The standard template also requires supply continuity and applicable regulatory consents. A supply issue must be notified when the supplier becomes aware of it, with a report within two Business Days; alternative supply requires Pharmac’s written consent under the relevant clause. Read these as template contractual conditions, with the actual agreement and special terms controlling, rather than universal statutory deadlines.

Commercial terms: net expenditure, disclosure and supply obligations

After a provisional agreement, Pharmac normally consults patients, whānau, Māori, clinicians, suppliers and Health NZ on the proposed population, access criteria, brand and implementation. Its April2026 policy requires formal consultation for first-time funding, proposed Schedule changes, material clinical or commercial impacts and other stated triggers. Consultation submissions may change the proposal. The Board or its delegate makes the final funding decision and Pharmac communicates the outcome under its policy. Only an approved Schedule change leads to the corresponding listing or amendment; a decision does not automatically create a funded listing. Reaching commercial agreement therefore does not yet create a final public commitment.

Provisional agreement, consultation and final decision

The HML lists medicines that public hospitals may use or must fund under its rules. Some products have prescriber or indication restrictions. Hospitals may set additional local specialist restrictions, but must not unreasonably limit funded access or undermine Pharmac decisions and must notify Pharmac. Pharmac may require a restriction to be changed or removed. Hospital prescriber restrictions can be met through the specified specialist, documented specialist recommendation or an approved hospital protocol. Defined emergency arrangements require reasonable attempts to contact the specialist; treatment beyond 24 hours must satisfy the specialist or protocol route. A current Special Authority approval can satisfy an HML indication restriction, but does not by itself waive a prescriber restriction. Restricted-eligibility (RS) forms are local checklists and must not be submitted to Pharmac or the Ministry of Health. Check the actual hospital’s documentation requirements. An indication waiver is assessed case by case where the intent is met; this differs from satisfying the prescriber restriction. HML listing alone does not establish stock, service capacity or immediate patient supply. Unlisted medicines or uses outside an indication restriction normally require a specific Part8 exception, such as approved NPPA or a defined continuation arrangement; a broad statement of clinical need is insufficient.

Hospital use: indication, prescriber and local execution checks

therapeutic subgroup decision; Pharmac; subsidy reduced/aligned; surcharge/switching possible; comparative therapeutic status; retained, switched or removed from funded listing

Reference pricing changes funded listing, not marketing consent

several products from one supplier considered together; Pharmac/supplier; cross-product economics; one/more applications may advance; portfolio terms and budget impact; bundled funding/variation

Portfolio negotiations concern products from the same supplier

funded units or spend threshold; Pharmac/supplier; per-unit rebate or cap settlement; usually no automatic criteria change; contract sales/expenditure data; continuing/revised agreement

Rebate reconciliation follows the actual funding contract

national HML listing; Health NZ hospital; procurement/operational cost; stock/protocol/service readiness; comply with HML; local restriction notice; adopt, protocol, exception

Hospital implementation has its own responsible provider

competitive procurement for items eligible for the tender; Pharmac/suppliers; bid price/subsidy reduction; principal brand subject to item-specific share, contract, alternative-brand allowance and exceptions; stock, transition, supply performance; multi-year PSS/brand switch

Annual Tender: eligible items and funded supply terms

Purpose: compare marginal health outcomes across diseases and products and allocate a limited budget to the best overall combination. Mechanism: the Factors, HTA/cost-utility analysis, relative ranking and commercial/budget feasibility. Boundary: OFI is not funding approval. There is no public, fixed, automatic ICER cutoff.

Fixed-budget cross-portfolio prioritisation

Purpose: combine several items from one supplier to improve budget and health outcomes. Mechanism: commercial terms may span products, and applications need not advance one by one in priority-list order. Boundary: a public page for one product usually cannot fully explain cross-product considerations; commercial confidentiality should be explicit.

Portfolio agreements

Purpose: target funded access to defined clinical circumstances, treatment sequences, specialists and care settings. Mechanism: community Special Authority applications, hospital indication/prescriber restrictions and renewal or continuation rules. Boundary: Special Authority approval is not Medsafe consent. HML restrictions and community Special Authority criteria may be related but are not necessarily identical.

Special Authority and HML restrictions

Pharmac may amend the Schedule on its own initiative or following an application, including access criteria, subsidy, indications, formulations or presentations, pack size, brand and removal from funded listing. Reference pricing may align the subsidy for a therapeutic subgroup with its lowest price. Where the ex-manufacturer price is higher, a patient or supply-chain surcharge may arise. Read each listing decision separately. The Annual Tender creates competition for many off-patent medicines and may award Principal Supply Status. The supplier overview describes up to about 95% of the funded market for about three years, but actual scope, term, transition and alternative-brand allowances depend on the item’s listing and contract. These figures are not a guaranteed purchase volume or sales forecast. Suppliers need not be New Zealand companies to bid, but must hold the necessary New Zealand regulatory consents before an award. Tender savings fund new medicines or expanded access, directly linking mature-market procurement with the innovation funding pool. Supply interruptions, contract expiry, new evidence or population changes may trigger commercial renegotiation, wider or narrower criteria, alternative-brand listings or exceptional supply arrangements.

Lifecycle: tender terms depend on the listing and contract

An NMA must demonstrate quality, safety and efficacy. Medsafe may request further information before deciding whether to recommend consent to the Minister's delegate. The 2026 target table gives 150 working days for the initial evaluation of a full NMA and 75 days for an abbreviated application, with additional time for company responses to requests for information and Medsafe's further evaluation. These are stage-specific targets, not an end-to-end approval promise. Medsafe explicitly states that it is not responsible for funding or purchasing. The sponsor still decides whether to supply the medicine in New Zealand after approval. Pharmac assessment may run in parallel with Medsafe review to reduce sequential waiting. Legal supply and funding decisions remain separate. From11August2026, specified product or packaging groups can qualify for a non-time-limited general labelling exemption, subject to their minimum label requirements. Controlled drugs and related products are excluded. New labels use the standard NMA/CMN process with the applicable group declaration and case-by-case evaluation; eligibility is not a blanket waiver of labelling, marketing consent or funding requirements. An eligible existing time-limited exemption remains valid until expiry, when the general exemption takes effect; an unchanged eligible approved label needs no new notification. Changes to a label with a general exemption require prior approval through CMN Labelling–G2 even when minor, and are not self-assessable G1 changes. General exemptions need no routine renewal but remain subject to later regulatory changes and do not permit inconsistent patient information. Medsafe’s 16 February 2026 policy clarifies data-sheet disclosure of excipients with known effects: use the EMA Annex and Label Statements Database, state quantities in section 2, and describe the effects in section 4.4 with CMI updates where appropriate. It recommends the lower threshold when the two references differ, and specifies the LSD threshold of 3 ppm or more for gluten-containing ingredients. This does not change package-labelling requirements in the LSD; consult the current references for the actual excipient. The ordinary abbreviated NMA route is distinct from consent by verification. It relies on complete, unredacted English assessment reports for an eligible intermediate- or higher-risk medicine approved by a recognised regulator within the preceding ten years, with the required product consistency; Medsafe still makes an independent decision. Priority assessment may be considered for significant clinical need, significant taxpayer savings, or medicines manufactured in New Zealand for export, subject to the stated criteria and available assessment resources. Ordinary CMNs are not eligible; section24(5) referrals can use the NMA priority criteria. Priority does not itself grant consent or funding. Section23 provisional consent lasts no more than two years and each renewal can be for up to two years. The NMA guide asks sponsors to apply for renewal at least three months before expiry and generally seek full consent within six years; these are guidance expectations, not an automatic renewal or a statutory six-year cap. Keep provisional consent current while full consent is assessed. For material changes, current section24 sets a 64-working-day distribution restriction, subject to the statutory exceptions or prior written Director-General consent, and a 32-working-day window to request further information. A section24(5) referral requires the Ministerial route; expiry of a target alone is not consent. The 2023 CMN guide’s older 45-day wording must not replace the current Act. Use CMN Form A for non-biological medicines and Form B for biological or biotechnological medicines, with the applicable change category and declarations. An eligible stand-alone self-assessable change needs notification and receipt of payment before implementation; bundling it with an assessable change requires consent for the whole application. A new active ingredient, combination, strength, dose form, flavour or trade name may require a separate NMA. Changes to a label with a general exemption use assessable Labelling–G2 rather than self-assessable G1.

Medsafe: consent is separate from government funding

An NMA must demonstrate quality, safety and efficacy. Medsafe may request further information before deciding whether to recommend consent to the Minister's delegate. The 2026 target table gives 150 working days for the initial evaluation of a full NMA and 75 days for an abbreviated application, with additional time for company responses to requests for information and Medsafe's further evaluation. These are stage-specific targets, not an end-to-end approval promise. Medsafe explicitly states that it is not responsible for funding or purchasing. The sponsor still decides whether to supply the medicine in New Zealand after approval. Pharmac assessment may run in parallel with Medsafe review to reduce sequential waiting. Legal supply and funding decisions remain separate. From11August2026, specified product or packaging groups can qualify for a non-time-limited general labelling exemption, subject to their minimum label requirements. Controlled drugs and related products are excluded. New labels use the standard NMA/CMN process with the applicable group declaration and case-by-case evaluation; eligibility is not a blanket waiver of labelling, marketing consent or funding requirements. An eligible existing time-limited exemption remains valid until expiry, when the general exemption takes effect; an unchanged eligible approved label needs no new notification. Changes to a label with a general exemption require prior approval through CMN Labelling–G2 even when minor, and are not self-assessable G1 changes. General exemptions need no routine renewal but remain subject to later regulatory changes and do not permit inconsistent patient information. Medsafe’s 16 February 2026 policy clarifies data-sheet disclosure of excipients with known effects: use the EMA Annex and Label Statements Database, state quantities in section 2, and describe the effects in section 4.4 with CMI updates where appropriate. It recommends the lower threshold when the two references differ, and specifies the LSD threshold of 3 ppm or more for gluten-containing ingredients. This does not change package-labelling requirements in the LSD; consult the current references for the actual excipient. The ordinary abbreviated NMA route is distinct from consent by verification. It relies on complete, unredacted English assessment reports for an eligible intermediate- or higher-risk medicine approved by a recognised regulator within the preceding ten years, with the required product consistency; Medsafe still makes an independent decision. Priority assessment may be considered for significant clinical need, significant taxpayer savings, or medicines manufactured in New Zealand for export, subject to the stated criteria and available assessment resources. Ordinary CMNs are not eligible; section24(5) referrals can use the NMA priority criteria. Priority does not itself grant consent or funding. Section23 provisional consent lasts no more than two years and each renewal can be for up to two years. The NMA guide asks sponsors to apply for renewal at least three months before expiry and generally seek full consent within six years; these are guidance expectations, not an automatic renewal or a statutory six-year cap. Keep provisional consent current while full consent is assessed. For material changes, current section24 sets a 64-working-day distribution restriction, subject to the statutory exceptions or prior written Director-General consent, and a 32-working-day window to request further information. A section24(5) referral requires the Ministerial route; expiry of a target alone is not consent. The 2023 CMN guide’s older 45-day wording must not replace the current Act. Use CMN Form A for non-biological medicines and Form B for biological or biotechnological medicines, with the applicable change category and declarations. An eligible stand-alone self-assessable change needs notification and receipt of payment before implementation; bundling it with an assessable change requires consent for the whole application. A new active ingredient, combination, strength, dose form, flavour or trade name may require a separate NMA. Changes to a label with a general exemption use assessable Labelling–G2 rather than self-assessable G1.

Medsafe: consent is separate from government funding

An NMA must demonstrate quality, safety and efficacy. Medsafe may request further information before deciding whether to recommend consent to the Minister's delegate. The 2026 target table gives 150 working days for the initial evaluation of a full NMA and 75 days for an abbreviated application, with additional time for company responses to requests for information and Medsafe's further evaluation. These are stage-specific targets, not an end-to-end approval promise. Medsafe explicitly states that it is not responsible for funding or purchasing. The sponsor still decides whether to supply the medicine in New Zealand after approval. Pharmac assessment may run in parallel with Medsafe review to reduce sequential waiting. Legal supply and funding decisions remain separate. From11August2026, specified product or packaging groups can qualify for a non-time-limited general labelling exemption, subject to their minimum label requirements. Controlled drugs and related products are excluded. New labels use the standard NMA/CMN process with the applicable group declaration and case-by-case evaluation; eligibility is not a blanket waiver of labelling, marketing consent or funding requirements. An eligible existing time-limited exemption remains valid until expiry, when the general exemption takes effect; an unchanged eligible approved label needs no new notification. Changes to a label with a general exemption require prior approval through CMN Labelling–G2 even when minor, and are not self-assessable G1 changes. General exemptions need no routine renewal but remain subject to later regulatory changes and do not permit inconsistent patient information. Medsafe’s 16 February 2026 policy clarifies data-sheet disclosure of excipients with known effects: use the EMA Annex and Label Statements Database, state quantities in section 2, and describe the effects in section 4.4 with CMI updates where appropriate. It recommends the lower threshold when the two references differ, and specifies the LSD threshold of 3 ppm or more for gluten-containing ingredients. This does not change package-labelling requirements in the LSD; consult the current references for the actual excipient. The ordinary abbreviated NMA route is distinct from consent by verification. It relies on complete, unredacted English assessment reports for an eligible intermediate- or higher-risk medicine approved by a recognised regulator within the preceding ten years, with the required product consistency; Medsafe still makes an independent decision. Priority assessment may be considered for significant clinical need, significant taxpayer savings, or medicines manufactured in New Zealand for export, subject to the stated criteria and available assessment resources. Ordinary CMNs are not eligible; section24(5) referrals can use the NMA priority criteria. Priority does not itself grant consent or funding. Section23 provisional consent lasts no more than two years and each renewal can be for up to two years. The NMA guide asks sponsors to apply for renewal at least three months before expiry and generally seek full consent within six years; these are guidance expectations, not an automatic renewal or a statutory six-year cap. Keep provisional consent current while full consent is assessed. For material changes, current section24 sets a 64-working-day distribution restriction, subject to the statutory exceptions or prior written Director-General consent, and a 32-working-day window to request further information. A section24(5) referral requires the Ministerial route; expiry of a target alone is not consent. The 2023 CMN guide’s older 45-day wording must not replace the current Act. Use the current form to distinguish assessable CMNs from eligible self-assessable notifications. An eligible stand-alone self-assessable change requires notification and receipt of payment before implementation; combining it with an assessable change requires consent for the whole application first. A new active ingredient, combination, strength, dose form, flavour or trade name can require a separate NMA rather than a CMN. General-exemption label changes retain their specific prior-approval rule.

Medsafe: consent is separate from government funding

listing agreement term; Pharmac/supplier; net price and protection may change; supply/access continuity risk; supply, forecast, price, performance; renew, replace, vary or delist

Contract expiry concerns funding-listing terms, not marketing authorisation

Eligibility requires full marketing authorisations from at least two recognised regulatory authorities and a New Zealand product identical in all material aspects to the overseas products. Conditional, provisional or emergency approvals cannot satisfy the required full authorisations. Medsafe performs minimal verification, but the Minister's delegate still makes an independent national decision. The application may be granted, refused, or withdrawn and resubmitted through the full or abbreviated route. The validation decision is due within 10 working days after the application and validation fee are received, excluding applicable pauses. Evaluation starts when the application fee is paid: initial evaluation/RFI by working day 20 and a decision by working day 30 or earlier. The clock stops while an RFI is answered; the response period is 30 working days. Medsafe issues one RFI round. Minor differences in indication or dosage wording can be acceptable; Medsafe generally starts with the more restrictive wording, and a subset of initially approved indications may be proposed. This differs from adding new/expanded indications or a new/modified dosage regimen as a clinical variation, which cannot be included in a verification application. Generics/biosimilars must match the New Zealand innovator’s indication and dosing. Usual post-approval change procedures still apply. Planning implication: establish the two reference approvals, product sameness, New Zealand Module 1 and variation history in advance. Otherwise the assumed 30-day pathway may not apply.

The 2026 verification pathway: a reliance route with a separate national decision

The four dimensions are Need, Health Benefits, Costs and Savings, and Suitability. They are considered at the individual, family/whānau/society and health-system levels. Need includes disease severity, existing funded alternatives and health disparities affecting Māori, Pacific peoples and others. Health benefits include effects on patients and wider populations; costs and savings cover pharmaceutical and wider health-system consequences; suitability includes practical administration and workforce considerations. Cost-utility analysis helps compare incremental value, but the relevance of the Factors varies with the decision and requires judgement. Pharmac does not use a fixed cost-effectiveness threshold; funding choices aim at the best health outcomes achievable within the available budget. Cross-country distinction: a favourable ICER does not itself secure Pharmac funding. Japan uses cost-effectiveness evaluation to adjust prices for designated products already listed in the NHI; that is a different decision from selecting investments within Pharmac’s budget.

Factors for Consideration: a broader assessment than the ICER

After a provisional agreement, Pharmac normally consults patients, whānau, Māori, clinicians, suppliers and Health NZ on the proposed population, access criteria, brand and implementation. Its April2026 policy requires formal consultation for first-time funding, proposed Schedule changes, material clinical or commercial impacts and other stated triggers. Consultation submissions may change the proposal. The Board or its delegate makes the final funding decision and Pharmac communicates the outcome under its policy. Only an approved Schedule change leads to the corresponding listing or amendment; a decision does not automatically create a funded listing. Reaching commercial agreement therefore does not yet create a final public commitment.

Provisional agreement, consultation and final decision

new evidence, unmet need, implementation feedback; Pharmac for national funding/access criteria; Health NZ for hospital implementation; may change net expenditure; Pharmac may amend national SA/HML criteria; hospitals apply the HML and any permitted local restrictions; Clinical rationale and relevant evidence or implementation feedback for the proposed change; Retain or amend national Schedule criteria; hospital implementation is a separate step

Separate national access-criteria decisions from hospital implementation

A supplier, clinician or another person in New Zealand may apply. Company applications usually include clinical trials and a price offer. Pharmac assesses the evidence and obtains independent clinical advice from PTAC or specialist advisory committees as needed, alongside research and economic analysis. A clinical recommendation helps the assessment but does not determine the final funding decision. Different indications for one molecule can have different application statuses, priority-list positions and access criteria. A single molecule-level funded/not-funded label is insufficient. Published provisional PTAC recommendations can precede the final committee-agreed record. Neither a provisional nor a final clinical recommendation is Pharmac’s confidential cross-portfolio ranking or a commitment to fund.

Funding applications: one medicine may have separate applications for different indications

A patient-specific approval is not necessarily limited to one year or required to renew annually. Current official guidance permits durations from one month to lifetime depending on the treatment and condition; renewal applies when the actual approval requires it.

Patient-exception outcomes allow different approval durations

Only authorised prescribers acting within their scope may apply for NPPA; rapid-assessment applications are limited to Health New Zealand clinicians. The individual needs exceptional clinical circumstances and must have exhausted all clinically suitable funded options, including relevant non-drug treatments. Patient preference alone is not a clinical exception. Approval is patient-specific; its duration depends on the treatment and condition and can range from one month to lifetime. For an approval that expires, renewal must address its previous criteria and clinical updates; Pharmac recommends applying one month before expiry. This is recommended lead time, not a statutory deadline or automatic renewal. The clinician notifies the patient; Pharmac also notifies the nominated pharmacy when approved. Rapid NPPA is for clinically urgent Health NZ hospital inpatients. Treatment needed within five working days is a guide to urgency, not a five-day decision guarantee. It cannot be used to accelerate discharge. Pharmac must assess rapid applications for any treatment claimable as a PCT pharmaceutical, including pharmaceutical cancer treatment, rituximab, infliximab and tocilizumab. Hospital rapid assessment is for eligible cases too urgent for a Pharmac decision in the clinically appropriate time and must apply the NPPA principles. Immediate life-threatening emergencies have a separate hospital-protocol route when the unlisted-indication and stock conditions are met, with notification to Pharmac. For long-term community treatment started with an HML medicine that is not community funded, the rapid-assessment guidance directs a 30-day discharge supply under rule3.5 and a standard NPPA community-funding application. Rule3.5 retains its original-pack or hospital discharge-policy exceptions and HML restrictions. The exceptional-circumstances framework retains Pharmac discretion and considers wider population benefits, opportunity costs and the available budget. Declined cases can seek process review or be resubmitted with materially changed clinical circumstances or evidence. A population-listing decline does not automatically end an existing NPPA approval; continued funding remains subject to its renewal conditions. The Exceptional Circumstances Framework is under review. The current timetable expects a second consultation in late November 2026; proposed reform is not an operative funding rule. Continue to use the current pathway and any medicine-specific conditions until a final change is confirmed.

NPPA: approval duration, urgent assessment and current reform status

Purpose: address individual cases that population policy cannot reasonably cover. Mechanism: waivers address the intent of funding criteria, while NPPA addresses exceptional clinical circumstances. Some medicines have a bespoke alternative-brand pathway with its own form and criteria; use that pathway where available. Without one, an NPPA request can be considered under the NPPA principles and Factors for Consideration, without automatic funding. Boundary: this should not be a company's routine launch plan and is not equivalent to compassionate supply.

NPPA, waivers and medicine-specific alternative-brand pathways

Purpose: keep the net price paid by Pharmac confidential, obtain a lower net unit price or manage total expenditure risk. These arrangements do not by themselves guarantee protection of an international list price. Mechanism: all-unit percentage rebates, threshold rebates, discounts and two-part pricing. Boundary: a Schedule subsidy does not represent the net price, and a rebate is not synonymous with an outcomes-based agreement.

Confidential rebates and expenditure management

Pharmac generally needs acceptable commercial terms before it can support a funding decision. A listing agreement may specify the agreed price, rebates, access criteria and protection against delisting or subsidy reductions. It may also cover several products from the same supplier. A rebate can reduce the net unit price for all funded units or apply only to expenditure above a threshold. Discounts, two-part pricing and other expenditure-management mechanisms are also possible. The Schedule shows public subsidies and prices, which do not reveal net costs after confidential rebates. Confidentiality is subject to applicable disclosure law and the actual agreement: the published standard template expressly recognises Official Information Act and other legal disclosure obligations. A portfolio agreement may change the apparent acceptable price of an individual product. Comparison pages should identify this as a system-level commercial feature rather than imply a universal net-price formula. The published listing agreement is a template. Product, price, listing date and minimum stock belong in Annex1; negotiated special terms belong in Annex2 and prevail over inconsistent standard terms. It does not prove any particular supplier’s executed price, rebate, term or stock commitment. The standard template also requires supply continuity and applicable regulatory consents. A supply issue must be notified when the supplier becomes aware of it, with a report within two Business Days; alternative supply requires Pharmac’s written consent under the relevant clause. Read these as template contractual conditions, with the actual agreement and special terms controlling, rather than universal statutory deadlines.

Commercial terms: net expenditure, disclosure and supply obligations

Pharmac sets specific funding criteria, while Health NZ receives and operates Special Authority applications. Each restricted medicine's Schedule listing links to its own Special Authority form. Criteria can cover indication, severity, previous therapy, specialist recommendation, dose or quantity and renewal. Approval may be time-limited or may not require routine renewal. A Special Authority waiver may suit a patient who misses a technical criterion but meets its intent. The prescriber uses the medicine’s ordinary form with supporting explanation and patient consent, and submits it to Pharmac; a waiver cannot be requested through the Electronic Special Authority system. Previously self-funded, overseas or compassionate treatment may qualify if the initial criteria were met before treatment began. A payable community claim requires the applicable prescription, Special Authority number, specialist or endorsement conditions and an eligible supplier agreement or statutory payment notice. Special Authority approval is not retrospective. If first dispensing precedes approval expiry, repeats completing up to three Months’ supply can remain subsidised after expiry unless the medicine has been delisted. Supply periods and dispensing quantities are separate. First dispensing must occur within three Months of the prescription. The rules allow up to 12 Months’ subsidised treatment where no legal supply limit applies, subject to dispensing rules; that is not permission to dispense a year at once. Where no legal dispensing maximum applies, a single dispensing is generally limited to three Months unless otherwise specified. In these Schedule rules, a capitalised Month means 30 consecutive days. Item-specific frequency, controlled-drug limits, modified dispensing and discharge exceptions still apply; check the actual listing and prescription.

Special Authority: application route, expiry and dispensing are separate checks

The HML lists medicines that public hospitals may use or must fund under its rules. Some products have prescriber or indication restrictions. Hospitals may set additional local specialist restrictions, but must not unreasonably limit funded access or undermine Pharmac decisions and must notify Pharmac. Pharmac may require a restriction to be changed or removed. Hospital prescriber restrictions can be met through the specified specialist, documented specialist recommendation or an approved hospital protocol. Defined emergency arrangements require reasonable attempts to contact the specialist; treatment beyond 24 hours must satisfy the specialist or protocol route. A current Special Authority approval can satisfy an HML indication restriction, but does not by itself waive a prescriber restriction. Restricted-eligibility (RS) forms are local checklists and must not be submitted to Pharmac or the Ministry of Health. Check the actual hospital’s documentation requirements. An indication waiver is assessed case by case where the intent is met; this differs from satisfying the prescriber restriction. HML listing alone does not establish stock, service capacity or immediate patient supply. Unlisted medicines or uses outside an indication restriction normally require a specific Part8 exception, such as approved NPPA or a defined continuation arrangement; a broad statement of clinical need is insufficient.

Hospital use: indication, prescriber and local execution checks

Only authorised prescribers acting within their scope may apply for NPPA; rapid-assessment applications are limited to Health New Zealand clinicians. The individual needs exceptional clinical circumstances and must have exhausted all clinically suitable funded options, including relevant non-drug treatments. Patient preference alone is not a clinical exception. Approval is patient-specific and generally time-limited. The clinician notifies the patient; Pharmac also notifies the nominated pharmacy when approved. Renewal must address the previous approval's criteria and clinical updates; Pharmac recommends submitting one month before expiry. That is recommended lead time, not a new universal statutory deadline or automatic continuation. Rapid NPPA is for clinically urgent Health NZ hospital inpatients. Treatment needed within five working days is a guide to urgency, not a five-day decision guarantee. It cannot be used to accelerate discharge. Pharmac must assess rapid applications for any pharmaceutical cancer treatment, rituximab, infliximab or tocilizumab. Other eligible cases may use the hospital’s rapid process where available. Immediate life-threatening emergencies have a separate hospital-protocol route when the unlisted indication and stock conditions are met, with notification to Pharmac. For long-term community treatment started with an HML medicine that is not community funded, the rapid-assessment guidance directs a 30-day discharge supply under rule3.5 and a standard NPPA community-funding application. Rule3.5 retains its original-pack or hospital discharge-policy exceptions and HML restrictions. The exceptional-circumstances framework retains Pharmac discretion and considers wider population benefits, opportunity costs and the available budget. Declined cases can seek process review or be resubmitted with materially changed clinical circumstances or evidence. A population-listing decline does not automatically end an existing NPPA approval; continued funding remains subject to its renewal conditions.

NPPA: ordinary, rapid and emergency routes have different conditions

Pharmac may amend the Schedule on its own initiative or following an application, including access criteria, subsidy, indication or presentation, pack, brand and delisting. Reference pricing may align the subsidy for a therapeutic subgroup with its lowest price. Where the ex-manufacturer price is higher, a patient or supply-chain surcharge may arise. Read each listing decision separately. The Annual Tender creates competition for many off-patent medicines and may award Principal Supply Status. The supplier overview describes up to about 95% of the funded market for about three years, but actual scope, term, transition and alternative-brand allowances depend on the item’s listing and contract. These figures are not a guaranteed purchase volume or sales forecast. Tender savings fund new medicines or expanded access, directly linking mature-market procurement with the innovation funding pool. Supply interruptions, contract expiry, new evidence or population changes may trigger commercial renegotiation, wider or narrower criteria, alternative-brand listings or exceptional supply arrangements.

Lifecycle: tender terms depend on the listing and contract

Purpose: obtain lower prices and supply commitments through off-patent competition and release funding. Mechanism: competitive tender or RFP, a specified supply-status term and brand transition. Hospital DV limits, alternative-brand allowances and exceptions follow the actual Schedule listing and national contract; non-supply and Pharmac-approved exceptions can permit alternative brands. Do not turn the overview’s approximately 95% share into a universal volume guarantee. Boundary: Pharmac may retain alternative brands and individual exceptions. This is not an absolute legal monopoly.

Principal Supply Status: contractual scope and exceptions

Prescribers apply and supply the clinical evidence; they do not thereby grant NPPA funding. Pharmac or the applicable eligible hospital rapid route decides under the relevant framework. The decision is patient-specific but has wider budget effects and does not establish a population listing.

Patient exceptions retain decision and funding boundaries

The tender overview is a general explanation. PSS access depends on the actual listing and contract, including alternative-brand allowances and exceptions; an approximate market share does not guarantee purchases.

Tender market share is subject to actual contract terms

An NMA must demonstrate quality, safety and efficacy. Medsafe may request further information before deciding whether to recommend consent to the Minister's delegate. The 2026 target table gives 150 working days for the initial evaluation of a full NMA and 75 days for an abbreviated application, with additional time for company responses to requests for information and Medsafe's further evaluation. These are stage-specific targets, not an end-to-end approval promise. Medsafe explicitly states that it is not responsible for funding or purchasing. The sponsor still decides whether to supply the medicine in New Zealand after approval. Pharmac assessment may run in parallel with Medsafe review to reduce sequential waiting. Legal supply and funding decisions remain separate. From11August2026, specified product or packaging groups can qualify for a non-time-limited general labelling exemption, subject to their minimum label requirements. Controlled drugs and related products are excluded. New labels use the standard NMA/CMN process with the applicable group declaration and case-by-case evaluation; eligibility is not a blanket waiver of labelling, marketing consent or funding requirements. An eligible existing time-limited exemption remains valid until expiry, when the general exemption takes effect; an unchanged eligible approved label needs no new notification. Changes to a label with a general exemption require prior approval through CMN Labelling–G2 even when minor, and are not self-assessable G1 changes. General exemptions need no routine renewal but remain subject to later regulatory changes and do not permit inconsistent patient information. Medsafe’s 16 February 2026 policy clarifies data-sheet disclosure of excipients with known effects: use the EMA Annex and Label Statements Database, state quantities in section 2, and describe the effects in section 4.4 with CMI updates where appropriate. It recommends the lower threshold when the two references differ, and specifies the LSD threshold of 3 ppm or more for gluten-containing ingredients. This does not change package-labelling requirements in the LSD; consult the current references for the actual excipient.

Medsafe: consent is separate from government funding

New indication or expanded access Proposed new indication or change to funding criteria Medsafe for consent and changes; Pharmac for funding Funding price or subsidy terms require a separate Pharmac decision or agreement Regulatory approval does not automatically expand funded eligibility Evidence for the regulatory change; separate clinical and economic information for any funding proposal Regulatory and funding decisions can differ

New indications: separate consent from funded access

Eligibility requires full marketing authorisations from at least two recognised regulatory authorities and a New Zealand product identical in all material aspects to the overseas products. Conditional, provisional or emergency approvals cannot satisfy the required full authorisations. Medsafe performs minimal verification, but the Minister's delegate still makes an independent national decision. The application may be granted, refused, or withdrawn and resubmitted through the full or abbreviated route. The validation decision is due within 10 working days after the application and validation fee are received, excluding applicable pauses. Evaluation starts when the application fee is paid: initial evaluation/RFI by working day 20 and a decision by working day 30 or earlier. The clock stops while an RFI is answered; the response period is 30 working days. Medsafe issues one RFI round. Minor differences in indication or dosage wording can be acceptable; Medsafe generally starts with the more restrictive wording, and a subset of initially approved indications may be proposed. This differs from adding new/expanded indications or a new/modified dosage regimen as a clinical variation, which cannot be included in a verification application. Generics/biosimilars must match the New Zealand innovator’s indication and dosing. Usual post-approval change procedures still apply. Planning implication: establish the two reference approvals, product sameness, New Zealand Module 1 and variation history in advance. Otherwise the assumed 30-day pathway may not apply.

The 2026 verification pathway: a reliance route with a separate national decision

Purpose: accelerate local consent for an NMA fully approved by two recognised regulators where the products are materially the same. Mechanism: reliance-based verification, New Zealand-specific compliance and an independent national decision. Boundary: consent is not automatic. Material product differences and ineligible authorisations can exclude an application. Minor indication/dosage wording differences and a subset of initially approved indications may be acceptable; new/extended indications or new/modified dosage regimens submitted as clinical variations are excluded.

Verification pathway

NPPA addresses exceptional clinical circumstances for an individual. It supplements the population-level Schedule process and assesses each case using the Factors for Consideration. A Schedule criteria waiver differs from NPPA: a waiver follows the intent of existing criteria; NPPA can address a patient's need that the current Schedule cannot meet. Section 29 allows supply for a known patient on the request of a medical practitioner, nurse practitioner or pharmacist prescriber caring for that patient. Section 29A covers an unapproved medicine listed in the Pharmaceutical Schedule as an alternative to an approved medicine in short supply; any authorised prescriber may request it for a patient in their care. For section 29/29A supply, the importer or manufacturer retains patient, prescriber and place-of-supply records, which Medsafe may request. As soon as practicable after each supply month, it reports medicine names, dose form, strength, pack size, supply month/year and quantity under section 29B. Patient names are not part of that routine subset. Prescribers must explain unapproved use and obtain informed consent. Boundary: section 29 is a legal supply exception and does not automatically provide Pharmac funding. NPPA is a funding exception and does not automatically waive regulatory or supply obligations. Section 25 separately permits an authorised prescriber to procure medicine for a known, identifiable patient within their scope of practice. Medsafe distinguishes this from section 29/29A supply: use of an approved medicine for an unapproved purpose does not itself require a report to Medsafe. The applicable consent and other supply obligations remain.

Named Patient Pharmaceutical Assessment (NPPA) and unapproved medicines

An NMA must demonstrate quality, safety and efficacy. Medsafe may request further information before deciding whether to recommend consent to the Minister's delegate. The 2026 target table gives 150 working days for the initial evaluation of a full NMA and 75 days for an abbreviated application, with additional time for company responses to requests for information and Medsafe's further evaluation. These are stage-specific targets, not an end-to-end approval promise. Medsafe explicitly states that it is not responsible for funding or purchasing. The sponsor still decides whether to supply the medicine in New Zealand after approval. Pharmac assessment may run in parallel with Medsafe review to reduce sequential waiting. Legal supply and funding decisions remain separate. From11August2026, specified product or packaging groups can qualify for a non-time-limited general labelling exemption, subject to their minimum label requirements. Controlled drugs and related products are excluded. New labels use the standard NMA/CMN process with the applicable group declaration and case-by-case evaluation; eligibility is not a blanket waiver of labelling, marketing consent or funding requirements. An eligible existing time-limited exemption remains valid until expiry, when the general exemption takes effect; an unchanged eligible approved label needs no new notification. Changes to a label with a general exemption require prior approval through CMN Labelling–G2 even when minor, and are not self-assessable G1 changes. General exemptions need no routine renewal but remain subject to later regulatory changes and do not permit inconsistent patient information.

Medsafe: consent is separate from government funding

Only authorised prescribers acting within their scope may apply for NPPA; rapid-assessment applications are limited to Health New Zealand clinicians. The individual needs exceptional clinical circumstances and must have exhausted all clinically suitable funded options, including relevant non-drug treatments. Patient preference alone is not a clinical exception. Approval is patient-specific and generally time-limited. The clinician notifies the patient; Pharmac also notifies the nominated pharmacy when approved. Renewal must address the previous approval's criteria and clinical updates; Pharmac recommends submitting one month before expiry. That is recommended lead time, not a new universal statutory deadline or automatic continuation.

Preserve NPPA applicant, alternative-treatment and renewal conditions

The8 October2026 notice opens the annual-tender portal for practice until26 October2026 at16:00 New Zealand time. It uses2025/26 medicines for the exercise, and submitted practice bids are not actual bids. New suppliers need company registration for the e-portal; previous participants from2016/17 onwards may use their existing account. The notice expects the final2026/27 ITT in early November2026. Check its actual release and final terms before treating a practice submission or draft product list as a funding or supply commitment.

Separate the practice tender from a real bid

Both recognised-authority initial full marketing authorisations must fall within four years before submission. Reliance-only approvals, including TGA COR, MHRA IRP and HSA abridged/verification, do not qualify as full evaluation. Joint work-sharing can qualify only with the required complete assessment-report sets. An initially provisional approval cannot be used merely because it later became full. The pathway also excludes cases requiring independent New Zealand benefit-risk assessment, including specified blood-derived, exclusively paediatric/pregnancy, gene-therapy and personalised products. The list is not exhaustive; seek advice for the precise product and risk-management requirements. Validation starts on payment of the validation fee and allows ten working days excluding missing-information stops. Evaluation Day0 is application-fee receipt; the Day20 RFI,30-day response and Day30 decision framework uses working days in New Zealand time, with the response clock stop. Acceptance and fees do not guarantee consent or Pharmac funding.

Check full-approval eligibility and fee-based verification clocks

Pharmac's TAP page describes a four-year improvement programme, with first-year aims to reduce old applications, update acceptance/triage, and introduce an18-month timeframe target for ranking. This is a programme target for ranking, not a promise to fund every application within18 months. Budget, supplier agreement and the applicable decision process remain separate. The programme also aims to review the Exceptional Circumstances Framework; that stated review does not itself replace current NPPA criteria or create an automatic funding route.

Treat the TAP ranking target separately from funding approval

The2026/27 draft-tender notice records a decision to remove Alternative Commercial Proposals from2026/27 and future annual ITTs. The consultation closed10 September2026; it is not a currently open final tender. Other product lists and proposed special terms remain draft until the final ITT. Existing principal-supply price protections, brand-change consultation, eligibility and listing dates require the actual item/contract. Indicative historical usage is not a guarantee of sales or awarded volume.

Separate the ACP decision from draft tender terms

The General Health Law consolidated through 15 January 2026 states that sanitary registration initially lasts five years and may be renewed in ten-year periods on application. Product status still needs a current COFEPRIS record.

Corrected the registration lifecycle check; renewal is not a fresh CNIS listing or proof of purchase and delivery.

The ordinance published on 21 September 2026 took effect mainly on 22 September. ApBetrO sections 17 and 35c require pharmacies to preserve medicine quality and temperature in courier delivery and mail order, including risk-based cold-chain transport. Separately, AMPreisV section 3a requires a proposal on pharmacy remuneration by 1 January 2028 and annually thereafter; it sets no automatic fee increase.

Added a pharmacy supply check for delivery route, temperature control and cold-chain handoff. This does not change marketing authorisation, the manufacturer's negotiated reimbursement amount or an individual patient's coverage; verify those decisions separately.

HSLF-FS 2026:23 applies from 1 October 2026 and replaces TLVFS 2008:2. New-medicine applications must state Swedish prevalence and incidence for all approved indications and the requested groups, intended three-party deliberations, reasons for restricted subsidy, and the justification for the economic comparator.

Added a conditional simplified application branch and JCA non-duplication check. Verify eligibility and evidence requirements; the economic template is optional and subsidy still needs a TLV decision.

The main HSLF-FS 2026:14 and 2026:16 provisions apply from 1 October 2026 to interchangeable medicines. Conditional ceiling reductions and a SEK 30 package floor are distinct from individual medicine prices. Indexation of that floor begins on 1 January 2028; the separate conditional ceiling CPI increase first applies in 2027.

Added a dated transition check to pharmacy and lifecycle detail. Verify the applicable ceiling, company price application and TLV decision separately. New generic-competition notifications follow TLV's published monthly cutoff; a preliminary transition list is not a product price decision.

CONITEC's instructions revised on 14 September require the formal dossier through the Ministry protocol into SEI/MS and editable .xlsm or .trex economic and budget-impact models. Supplementary model email must reference the registered process and does not replace formal submission. This is an instruction-revision date, not a separately stated legal commencement.

Added formal-protocol and model-audit checks before SUS assessment. Preserve the NUP and required forms, enable required macros and leave model cells and formulas unlocked. The e-GITS form remains listed. Conflicting attachment-size instructions remain unresolved, so no universal upload limit is asserted.

HAS now separates initial requests, renewals and new-data dossiers. Its 1 September instructions accept the former single model until 1 October 2026; new synthesis-report and summary templates apply to renewal dossiers submitted from 24 October. Continuity after authorisation and withdrawal use dedicated Sésame forms.

Added purpose-specific filing and dated template checks to the early-access branch. These procedural transitions do not themselves grant early access or routine reimbursement.

EMA announced the pilot on 28 August and launched it in September 2026 for planned initial marketing-authorisation submissions from February 2027 to September 2028. Participation requires agreement between the applicant, rapporteurs and EMA. The guidance is dated 24 August, first published 2 September and revised 7 September; these are document dates, not a universal legal commencement date.

Added an optional preparation route to the centralised regulatory detail. Agreed participants use the pilot's rapporteur allocation, written dialogue, joint readiness meeting and Letter of Intent timetable. Keep ordinary applications and national pricing or reimbursement decisions separate.

Section 130b(7a) permits either party to terminate agreements or arbitration awards establishing reimbursement amounts by 29 July 2026, by the end of 1 October 2026. This includes medicines no longer marketed in Germany. A replacement must be agreed without delay; the old agreement remains in effect until the new one takes effect.

Added a dated checkpoint to negotiation and legacy-contract review. This is an Atlas clarification of the existing law, not a new September policy or an automatic termination of every agreement.

The Commission's 19 August guidance clarifies early information for products within JCA scope: declare scope in the EMA Eligibility and Letter of Intent forms, notify the HTA Secretariat in parallel, and upload the forms using a product-specific platform link. Changes to the planned submission date or withdrawal must also be communicated.

Added the parallel JCA/EMA pre-submission handoff to the regulatory decision's operating detail in the 14 EU markets covered by Atlas. This is a shared EU preparation step; national assessment, pricing and reimbursement decisions remain distinct.

NMPA Announcement No. 50 of 2026, dated 21 May and published 8 June 2026, brings the revised Good Clinical Practice standard into effect on 1 September 2026 and repeals the 2020 standard. It makes participant rights, safety and wellbeing paramount and requires quality by design, identification of critical quality factors, proportionate quality management, reliable and traceable data, fit-for-purpose computerized systems, and auditable duties across sponsors, investigators, institutions, ethics committees, laboratories and contracted service providers.

Atlas now treats current-GCP compliance as an upstream clinical-evidence and lifecycle gate before marketing authorization. The transition can affect trial initiation, conduct, change control, safety reporting, suspension or termination and the acceptability of the final authorization dossier; it does not itself create reimbursement. The official announcement date is 21 May 2026, publication date 8 June and effective date 1 September; the separate Atlas content-update date is 4 September 2026.

NICE published interim methods statement PMG51 on 27 August 2026. For technology appraisals and highly specialised technologies with an invitation to participate issued after publication, adult reference-case analyses must use the EQ-5D-5L descriptive system and the new UK 5L value set. Available 3L data must be mapped to 5L; 3L value-set utilities are not accepted as new-topic sensitivity scenarios. Topics already underway retain the former 5L-to-3L approach, and published guidance is not reopened solely for this change.

Atlas now makes the NICE topic start date an evidence-method gate, shows the required 5L value set and 3L-to-5L mapping direction for new topics, and preserves the prior method for ongoing topics. The official policy date is 27 August 2026; the separate Atlas content-update date is 28 August 2026.

ALPS now requires every awarded supplier to register on SAP Business Network and accept the Trading Relationship Request issued through the relevant PHI purchase order before transacting or invoicing. The sole-platform rollout started for Woodlands Health and Alexandra Hospital on 3 August 2026, expanded to NHG, NUHS, Synapxe, AIC and 1FSS on 17 August, and is scheduled for SingHealth and ALPS in January 2027.

Atlas now separates contract award and stock from supplier-network enablement, PO-linked relationship acceptance and a payable electronic invoice. A funded and delivered medicine can still fail the procurement-to-payment flow if this gate is not active.

Portaria GM/MS 12.085, dated 17 August 2026 and posted by the Ministry on 18 August, establishes minimum structure, organisation and responsibility requirements for centres that dilute ultra-high-cost oncology medicines and adds a specialised-service classification to CNES.

Atlas now treats AF-ONCO list status, acquisition modality, qualified dilution-site CNES status and treating-centre readiness as separate execution gates. The ordinance date is not being presented as evidence that every centre is already qualified.

Decree-Law 118/2026 was published on 17 June and entered into force on 1 July 2026, replacing the former SiNATS decree-law. It integrates applicable EU joint clinical assessments into the national evidence flow and creates a voluntary three-year pilot for coordinated AIM and public-funding assessment while retaining separate regulatory and financing decisions.

Atlas now uses Decree-Law 118/2026 as the controlling legal basis, shows EU clinical assessment as an input rather than Portugal's final value decision, and adds an optional parallel-assessment branch whose regulatory and funding outputs remain separate.

The current SGB V text effective from 30 July 2026 requires §130b agreements to address price and volume. If the parties do not agree a rule, a statutory annual adjustment can apply from year four. The reform also replaces the former §130e combination-discount mechanism with sickness-fund contracts for therapeutically comparable patent-protected medicine groups, and removes nationwide Praxisbesonderheit treatment from new §130b agreements while preserving defined legacy arrangements.

Atlas now separates the month-seven reimbursement amount from later price-volume adjustment and fund-specific patent-group contracting. Outpatient prescribing also distinguishes the legacy nationwide practice exception from the new contract-based economic-review treatment.

The PBS Ministerial-discretion page updated on 12 August 2026 confirms 5% reductions at the fifth and tenth anniversaries and a fifteenth-anniversary reduction of 26.1%, increasing to 30% from 1 April 2027. It also specifies the first-new-brand reduction formula, flow-on rules and the HPP request timetable for the April 2027 reduction day.

Atlas now shows the exact anniversary reductions, the first generic or biosimilar floor formula, same-drug/mechanism flow-on and the fact that Ministerial discretion requires a timed HPP request rather than creating an automatic exemption.

No new official policy for Mainland China was published on 6 August. Atlas revised the pathway on that date after reviewing existing NHSA material on the 2026 catalogue cycle. The latest cited official source was published on 31 May 2026.

The Mainland China pathway now distinguishes formal NRDL submission, expert review, national negotiation or bidding, agreement-period management and later VBP/follow-on procurement instead of treating reimbursement as one listing event.

The Health Insurance Policy Deliberation Committee approved pharmaceutical-pricing reforms that expand flexible price contracting and reinforce reassessment and lifecycle price management.

The Korea pathway now separates HIRA reimbursement assessment, RSA/CEA-exemption eligibility, NHIS price or contract negotiation, flexible-contract handling and later use-volume/reassessment events.

The Ministry of Health published the AF-ONCO framework and 2026 amendments for organising financing, acquisition, distribution and dispensing of selected high-cost oncology medicines.

The Brazil pathway now distinguishes conventional PCDT/APAC centre financing from AF-ONCO selection, central acquisition/distribution and local dispensing. APAC remains a Brazilian oncology authorisation/payment instrument—not the Asia-Pacific region.

Royal Decree 415/2026 established the national health-technology assessment framework, including separate clinical and non-clinical phases, procedural clocks and transition arrangements.

The Spain pathway now separates the evolving national HTA phases from the later CIPM financing/price decision and from autonomous-community or hospital implementation. The HTA output is evidence input; it is not itself the reimbursement decision.

Belgium's Early and Fast Access framework became effective on 1 March 2026, creating an earlier route for eligible medicines and patients while the routine price-and-reimbursement process continues.

The Belgium pathway now shows EEFA eligibility and patient intervention as a distinct branch rather than folding it into routine CRM/CTG reimbursement or Article 81/111 temporary agreements.